Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

Columbia Laboratories’ Shares Plunge 65% on Phase III Failure

  • Columbia Laboratories’ progesterone gel for the prevention of preterm birth in women with a previous preterm birth earlier than 35-weeks gestation failed in its Phase III trial. Prochieve did not achieve any reduction in the incidence of preterm birth at week 32, the primary endpoint, or at weeks 28, 35, and 37, secondary endpoints of the study.

    The company’s shares slid 65.72% to open trading at $1.58.

    "These study results are extremely disappointing. Despite solid evidence in this and other studies that Prochieve 8% effectively delivers progesterone to the uterus, there was no difference in the reduction of preterm birth incidence in patients with a previous preterm birth earlier than 35 weeks and treated with progesterone versus placebo at any endpoint," says Robert S. Mills, president and CEO of Columbia Laboratories.

    Of the 611 evaluable patients in this randomized, placebo-controlled, double-blind study, 302 received placebo and 309 received Prochieve 8%. The mean gestational age at delivery was approximately 37 weeks in both the active and placebo groups. This was an improvement from a mean of 30 weeks in the previous preterm birth for both groups. Over 60% of evaluable patients had a previous preterm birth at or below 32 weeks gestation.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »